Active Not Recruiting EARLY_PHASE1 INTERVENTIONAL 3-arm NCT06975319

Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers

A Prospective, Randomised, Placebo-controlled, Double-blind First in Human Trial Evaluating the Safety and Immunogenicity of V-212 Administered on Three Occasions in Healthy Adult Volunteers.

Sponsor: CR2O

Conditions Healthy Immunisation Against Streptococcus Pneumoniae

Interventions V-212 (or Placebo) administered by i.m injection (3 vaccinations) - high dose V-212 (or Placebo) administered by i.m injection (3 vaccinations) - low dose V-212 (or Placebo) administered by i.m injection (3 vaccinations) - medium dose

Updated 2 times since 2025 Last updated: Aug 25, 2025 Started: Jan 29, 2025 Primary completion: Dec 2, 2025 Completion: Jul 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Healthy and Immunisation Against Streptococcus Pneumoniae, this trial is ongoing. The trial is conducted by CR2O and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting EARLY_PHASE1

Status: Recruiting → Active Not Recruiting
Jun 2025 — Sep 2025 [monthly]

Recruiting EARLY_PHASE1

First recorded

Jan 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CR2O
Virometix

Data source: Virometix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ghent, Belgium